ArticleKidney international reports2024
Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07765914 (Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis.Frontiers in immunology · 2026Pooled it
- Ten tips for the diagnosis and management of nephrotic syndrome.Clinical kidney journal · 2026Review
- Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Retrospective study of treatment effectiveness and remission predictors of obinutuzumab in primary membranous nephropathy.BMC nephrology · 2026Article
- Obinutuzumab is effective for refractory primary membranous nephropathy.BMC nephrology · 2026Article
- Research Advances in Rituximab-Resistant Membranous Nephropathy.Kidney medicine · 2026Review
- Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome.Kidney international reports · 2026Article
- Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study.BMC nephrology · 2026Observational
- Response to the Letter to the Editor Entitled "Reconsideration of Response Assessment in Obinutuzumab-Treated Membranous Nephropathy".Kidney international reports · 2026Article
- Obinutuzumab as a Rescue Therapy in Anti-Rituximab Antibody-Positive Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Reconsideration of Response Assessment in Obinutuzumab-Treated Membranous Nephropathy.Kidney international reports · 2026Article
- Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy.Frontiers in immunology · 2026Article
- Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.American journal of nephrology · 2026Article
- Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series.Frontiers in medicine · 2026Article
- Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Retrospective analysis of serum NELL-1 and EXT1/2: no significant predictive value for treatment response in a cohort of membranous nephropathy patients.Renal failure · 2025Article
- Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.Kidney international reports · 2025Article
- Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.Clinical kidney journal · 2025Article
- Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.Clinical kidney journal · 2025Review
- The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease.Clinical kidney journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody in individuals with MN. Methods: We retrospectively analyzed data from 59 consecutive patients with primary MN who provided consent to receive Obinutuzumab and were followed for at least 6 months. The primary outcomes were complete (proteinuria <0.3 g/d) or partial (proteinuria <3.5 g/d with ≥ 50% reduction) remission of proteinuria. Results: Twenty patients received Obinutuzumab as initial therapy, and 39 patients were previously treated with at least 1 immunosuppressant (second-line therapy). Fifty patients (84.7%) achieved complete remission (CR) or partial remission (PR) of proteinuria during the median follow-up of 9.4 months. The likelihood of remission was significantly higher when Obinutuzumab was used as initial therapy than as second-line therapy after adjusting for the baseline estimated glomerular filtration rate (eGFR), 24-hour urinary protein levels, and anti-phospholipase A Conclusion: Obinutuzumab may represent a promising and well-tolerated therapeutic option for individuals with primary MN. The potential of Obinutuzumab was highlighted as an initial therapy for primary MN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.